BE1007315A6 - Pharmaceutical formulations containing acetylcysteine - Google Patents

Pharmaceutical formulations containing acetylcysteine Download PDF

Info

Publication number
BE1007315A6
BE1007315A6 BE9300754A BE9300754A BE1007315A6 BE 1007315 A6 BE1007315 A6 BE 1007315A6 BE 9300754 A BE9300754 A BE 9300754A BE 9300754 A BE9300754 A BE 9300754A BE 1007315 A6 BE1007315 A6 BE 1007315A6
Authority
BE
Belgium
Prior art keywords
acetylcysteine
weight
mannitol
flavor
composition according
Prior art date
Application number
BE9300754A
Other languages
French (fr)
Original Assignee
Menarini Farma Ind
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Menarini Farma Ind filed Critical Menarini Farma Ind
Priority to BE9300754A priority Critical patent/BE1007315A6/en
Application granted granted Critical
Publication of BE1007315A6 publication Critical patent/BE1007315A6/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0087Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/195Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid, pantothenic acid
    • A61K31/198Alpha-aminoacids, e.g. alanine, edetic acids [EDTA]

Abstract

Pharmaceutical formulation based on acetylcysteine composed of 10 to 20% byweight of N-acetylcysteine, 0.5 to 3% by weight of sodium saccharine, 5 to15% by weight of flavouring, 50 to 70% by weight of mannitol.

Description

       

   <Desc/Clms Page number 1> 
 



   DESCRIPTION 
Compositions pharmaceutique contenant de l'acétylcystéine La présente invention se rapporte à une composition pharmaceutique contenant de l'acétylcystéine, substance connue pour sa propriété de pouvoir fluidifier du mucus. 



  En médicine on utilise l'acétylcystéine comme mucolytique et expectorant dans le but de fluidifier les sécrétions visqueuses denses du système respiratoire en cas de bronchite et autres affections pulmonaires. 



  Comme médicament l'acétylcystéine est généralement administrée par voie orale sous forme de poudre, de granulé ou de comprimé soluble dans l'eau. 



  Toutefois l'acétylcystéine est une substance hautement acide, qui a en plus un gout extrêmement déplaisant, causé par le groupement sulfhydrile dans sa structure chimique, il est donc important de l'incorporer dans des formes orales faciles et agréables à absorber, d'autant plus que le médicament s'adresse aussi aux jeunes enfants. 



  Il a déjà été proposé d'ajouter à l'acétylcystéine du sucre ou du saccharose en vue d'en améliorer le goût, mais ces substances contiennent pas mal de calories et peuvent créer un problème lors de traitements longs chez les personnes qui souffrent de diabète par exemple. 



  Il existe donc une demande pour médicaments à base d'acétylcystéine qui ne contient pas de sucre, tout en ayant un goût agréable et sous une forme orale facile à absorber. La présente invention propose une composition à base d'acétylcystéine, sous forme de granulé, poudre ou comprimé, soluble dans l'eau, contenant un édulcorant synthétique, un dolcifiant ainsi qu'un arôme. 

 <Desc/Clms Page number 2> 

 



  Comme l'édulcorant et le dolcifiant doivent être des substances compatibles entre elles et avec l'acétylcystéine, il est important de sélectionner très soigneusement ces substances. 



  Des recherches approfondies ont démontrées qu'en utilisant dans des proportions bien spécifiques comme édulcorant la saccharine et comme dolcifiant le mannitol, on obtient une excellante formulation pharmaceutique. 



  En effet la valeur énergétique de la saccharine étant insignifiante et le mannitol n'étant pas resorbé par le tractus gastro-intestinal, cette composition ne comporte pas de contreindications. De plus on associera de   préférance   à cette composition un goût spécifique que le consommateur pourra reconnaître, par exemple l'arôme orange, et un colorant pour usage pharmaceutique. Il est clair que tout autre arôme, tel pêche, abricot, pamplemousse, citron ou autre goût de fruit, pourra également être utilisé La composition selon l'invention comporte (en pourcentages en poids) : de 10 à 20% de N-acétylcystéine de 0.5 à   3%   de saccharine sodique de 3 à 15% d'arôme de 50 à 70% de mannitol les parts en poids des composants totalisant 100. 



  La préparation de cette formulation sous forme de granulé se fait suivant les procédés classiques, bien connus par l'homme de l'art de l'industrie pharmaceutique. 



  La composition suivant l'invention sous forme de granulés est bien soluble dans l'eau à température ambiante et par conséquent facile à absorber et possède un goût agréable lui permettant d'être sans problèmes administrée aux jeunes enfants. Cette composition pourra avantageusement être conditionnée en sachets de 1 gramme ou de multiples de 1 gramme. 



  A titre d'exemple ci-après deux formulations type : Formulation de 1 gramme :   N-acéty1cystéine   200,0 mg
Saccharine sodique 15,0 mg
Arôme (orange) 100,0 mg
Mannitol 684,2 mg
Colorant   El 10 0, 8   mg 

 <Desc/Clms Page number 3> 

 conditionnée sous forme de granulés en sachets. 



  Formulation de 3 grammes :
N-acétylcystéine 600,0 mg
Saccharine sodique 40,0 mg
Arôme (fruit) 300,0 mg
Mannitol 2057,3 mg
Colorant El 10 2,7 mg conditionnée sous forme de granulés en sachets.



   <Desc / Clms Page number 1>
 



   DESCRIPTION
The present invention relates to a pharmaceutical composition containing acetylcysteine, a substance known for its property of being able to thin mucus.



  In medicine, acetylcysteine is used as a mucolytic and expectorant in order to thin the dense viscous secretions of the respiratory system in case of bronchitis and other pulmonary affections.



  As a medicine, acetylcysteine is usually administered orally as a powder, granule or water-soluble tablet.



  However acetylcysteine is a highly acidic substance, which in addition has an extremely unpleasant taste, caused by the sulfhydrile group in its chemical structure, it is therefore important to incorporate it in oral forms which are easy and pleasant to absorb, all the more more than the drug is also aimed at young children.



  It has already been proposed to add sugar or sucrose to acetylcysteine to improve taste, but these substances contain a lot of calories and can create a problem during long treatments in people who suffer from diabetes. for example.



  There is therefore a demand for medicines based on acetylcysteine which does not contain sugar, while having a pleasant taste and in an oral form which is easy to absorb. The present invention provides a composition based on acetylcysteine, in the form of a granule, powder or tablet, soluble in water, containing a synthetic sweetener, a dolcifier and a flavor.

 <Desc / Clms Page number 2>

 



  As the sweetener and the sweetener must be substances compatible with each other and with acetylcysteine, it is important to select these substances very carefully.



  Extensive research has shown that by using very specific proportions as a sweetener for saccharin and as a sweetener for mannitol, an excellent pharmaceutical formulation is obtained.



  Indeed the energy value of saccharin being insignificant and mannitol not being resorbed by the gastrointestinal tract, this composition does not have any contraindications. In addition, this composition will preferably be associated with a specific taste which the consumer will be able to recognize, for example the orange flavor, and a dye for pharmaceutical use. It is clear that any other flavor, such as peach, apricot, grapefruit, lemon or other taste of fruit, can also be used. The composition according to the invention comprises (in percentages by weight): from 10 to 20% of N-acetylcysteine 0.5 to 3% sodium saccharin 3 to 15% aroma 50 to 70% mannitol parts by weight of the components totaling 100.



  The preparation of this formulation in the form of granules is done according to conventional methods, well known to those skilled in the art of the pharmaceutical industry.



  The composition according to the invention in the form of granules is well soluble in water at room temperature and therefore easy to absorb and has a pleasant taste allowing it to be administered without problems to young children. This composition can advantageously be packaged in sachets of 1 gram or multiples of 1 gram.



  As an example below, two standard formulations: 1 gram formulation: N-acetylcysteine 200.0 mg
Saccharin sodium 15.0 mg
Flavor (orange) 100.0 mg
Mannitol 684.2 mg
Dye El 10 0.8 mg

 <Desc / Clms Page number 3>

 packaged in the form of granules in sachets.



  3 gram formulation:
N-acetylcysteine 600.0 mg
Saccharin sodium 40.0 mg
Flavor (fruit) 300.0 mg
Mannitol 2057.3 mg
Dye El 10 2.7 mg packaged in the form of granules in sachets.


    

Claims (5)

REVENDICATIONS 1. Composition pharmaceutique à base d'acétylcystéine, caractérisée en ce qu'elle est constituée par : N-acétylcystéine 10 à 20% en poids Saccharine sodique 0, 5 à 3 % en poids Arôme 5 à 15% en poids Mannitol 50 à 70% en poids CLAIMS 1. Pharmaceutical composition based on acetylcysteine, characterized in that it consists of: N-acetylcysteine 10 to 20% by weight Saccharin sodium 0.5 to 3% by weight Flavor 5 to 15% by weight Mannitol 50 to 70 % in weight 2. Composition suivant la revendication 1, caractérisée en ce qu'elle comporte également un colorant pour usage pharmaceutique. 2. Composition according to claim 1, characterized in that it also comprises a dye for pharmaceutical use. 3. Composition suivant la revendication 1 ou 2, caractérisée en ce qu'elle est conditionnée sous forme de granulés en sachets.  3. Composition according to claim 1 or 2, characterized in that it is packaged in the form of granules in sachets. 4. Médicament à base de la composition suivant la revendi-cation 3, caractérisé par la formulation suivante : N-acétylcystéine 200,0 mg Saccharine sodique 15,0 mg Arôme (orange) 100,0 mg Mannitol 684,2 mg Colorant El 10 0, 8 mg 4. Medicinal product based on the composition according to claim 3, characterized by the following formulation: N-acetylcysteine 200.0 mg Saccharin sodium 15.0 mg Flavor (orange) 100.0 mg Mannitol 684.2 mg Colorant El 10 0.8 mg 5. Médicament à base de la composition suivant la revendication 3, caractérisé par la formulation suivante : N-acéty1cystéine 600,0 mg Saccharine sodique 40,0 mg Arôme (fruit) 300,0 mg Mannitol 2057,3 mg Colorant E110 2,7 mg 5. Medicinal product based on the composition according to claim 3, characterized by the following formulation: N-acety1cysteine 600.0 mg Saccharin sodium 40.0 mg Flavor (fruit) 300.0 mg Mannitol 2057.3 mg Color E110 2.7 mg
BE9300754A 1993-07-19 1993-07-19 Pharmaceutical formulations containing acetylcysteine BE1007315A6 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
BE9300754A BE1007315A6 (en) 1993-07-19 1993-07-19 Pharmaceutical formulations containing acetylcysteine

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
BE9300754A BE1007315A6 (en) 1993-07-19 1993-07-19 Pharmaceutical formulations containing acetylcysteine

Publications (1)

Publication Number Publication Date
BE1007315A6 true BE1007315A6 (en) 1995-05-16

Family

ID=3887205

Family Applications (1)

Application Number Title Priority Date Filing Date
BE9300754A BE1007315A6 (en) 1993-07-19 1993-07-19 Pharmaceutical formulations containing acetylcysteine

Country Status (1)

Country Link
BE (1) BE1007315A6 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GR1007236B (en) * 2009-12-07 2011-04-08 Uni-Pharma Κλεων Τσετης Φαρμακευτικα Εργαστηρια Αβεε Με Δ.Τ. Uni-Pharma Abee, New pharmaceutical composition of n-acetylcysteine granules and production method thereof

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GR1007236B (en) * 2009-12-07 2011-04-08 Uni-Pharma Κλεων Τσετης Φαρμακευτικα Εργαστηρια Αβεε Με Δ.Τ. Uni-Pharma Abee, New pharmaceutical composition of n-acetylcysteine granules and production method thereof

Similar Documents

Publication Publication Date Title
AU635283B2 (en) Aqeous pharmaceutical suspension for substantially water insoluble pharmaceutical actives
RU2222323C2 (en) Composition for oral administration, method for reducing propionic acid compositions after tasting burning
US5569466A (en) Fill compositions for soft elastic gel capsules
FR2601876A1 (en) WATER-SOLUBLE PHARMACEUTICAL COMPOSITION CONTAINING N-ACETYL CYSTEINE AND CITRIC ACID
BE1015217A5 (en)
BE1000168A3 (en) Pharmaceutical composition containing soluble n-acetyl-cysteine and sorbitol.
ES2381851T3 (en) Procedure for obtaining an extract of blueberry pulp for use in the prevention and treatment of conditions such as caries, gingivitis and mild throat infections
KR100278875B1 (en) Silium Beverage Mix Composition Containing Granulated Base
US6919093B2 (en) Formulation
Neuvonen The effect of magnesium hydroxide on the oral absorption of ibuprofen, ketoprofen and diclofenac.
EP0339508A1 (en) Mouth-soluble pharmaceutical compositions containing acetylcysteine
JP2003026576A (en) Medicine having improved taste
CA2117762A1 (en) Pharmaceutical composition
BE1007315A6 (en) Pharmaceutical formulations containing acetylcysteine
CA1050889A (en) Pharmaceutical preparation containing asa and milk powder
BG60901B1 (en) Granulate containing sodium 2-mercaptoethanesulphonate as active substance and method for its preparation
FR2660195A1 (en) PHARMACEUTICAL CHEWING, ANTI-INFLAMMATORY AND / OR ANALGESIC COMPOSITION.
JP3751987B2 (en) Hangover prevention or improvement agent
BE1007926A3 (en) Pharmaceutical composition containing n-acetyl-cysteine.
ES2224261T3 (en) PHARMACEUTICAL COMPOSITION INTENDED FOR AN ADMINISTRATION BY ORAL ROUTE.
RU2166937C1 (en) Paracetamol-base drug
KANIWA et al. The bioavailabilities of aspirin from an aspirin aluminum and an aspirin tablets and the effects of food and aluminum hydroxide gel
JP2008074838A (en) Glucosyl hesperidin-containing composition
RU2241447C2 (en) Soluble carbonated medicinal formulation
AU2006202991B2 (en) Ibuprofen composition

Legal Events

Date Code Title Description
RE Patent lapsed

Owner name: A. MENARINI INDUSTRIE FARMACEUTICHE RIUNITE S.R.L

Effective date: 19950731